BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 35853681)

  • 1. Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study.
    Turnsek N; Devjak R; Edelbaher N; Osrajnik I; Unk M; Vidovic D; Jeric T; Janzic U
    Radiol Oncol; 2022 Aug; 56(3):371-379. PubMed ID: 35853681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT).
    Janžič U; Turnšek N; Dediu M; Donev IS; Lupu R; Teodorescu G; Ciuleanu TE; Pluzanski A
    Curr Oncol; 2022 Aug; 29(8):5833-5845. PubMed ID: 36005198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
    Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
    Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world treatment patterns of metastatic non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors.
    Shenolikar R; Liu S; Shah A; Tse J; Cao Y; Near A
    Cancer Med; 2023 Jan; 12(1):159-169. PubMed ID: 35702932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of patient characteristics, treatment patterns,
    Winfree KB; Sheffield KM; Cui ZL; Sugihara T; Feliciano J
    Curr Med Res Opin; 2022 Jan; 38(1):91-99. PubMed ID: 34544302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world data on treatment outcomes in
    Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
    Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec.
    Agulnik JS; Kasymjanova G; Pepe C; Hurry M; Walton RN; Sakr L; Cohen V; Small D
    Curr Oncol; 2021 Dec; 28(6):5179-5191. PubMed ID: 34940073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.
    Lu S; Shih JY; Jang TW; Liam CK; Yu Y
    Adv Ther; 2021 May; 38(5):2038-2053. PubMed ID: 33730350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT).
    Addeo A; Hochmair M; Janzic U; Dudnik E; Charpidou A; Płużański A; Ciuleanu T; Donev IS; Elbaz J; Aarøe J; Ott R; Peled N
    Ther Adv Med Oncol; 2021; 13():17588359211059874. PubMed ID: 35173817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations.
    Hayashi H; Nadal E; Gray JE; Ardizzoni A; Caria N; Puri T; Grohe C
    Clin Lung Cancer; 2022 Jan; 23(1):e69-e82. PubMed ID: 34865963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
    Walia M; Singhal MK; Kamle MS
    Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
    Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
    Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study.
    Subramanian J; Leighl NB; Choi YL; Chou TY; Gregg J; Hui R; Marchetti A; Silvey M; Makin R; Gillespie-Akar L; Taylor A; Kahangire DA; Bailey T; Chau M; Navani N
    Lung Cancer; 2023 Jan; 175():47-56. PubMed ID: 36455396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world management patterns in
    Lampaki S; Mountzios G; Georgoulias V; Rapti A; Xanthakis I; Baka S; Mavroudis D; Samantas E; Athanasiadis E; Zagouri F; Charpidou A; Somarakis A; Papista C; Nikolaou A; Anastasopoulou E; Paparepa Z; Syrigos KN
    Future Oncol; 2022 Sep; 18(28):3151-3164. PubMed ID: 35929414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients.
    Chang JW; Huang CY; Fang YF; Chang CF; Yang CT; Kuo CS; Hsu PC; Wu CE
    Thorac Cancer; 2022 Jul; 13(13):1888-1897. PubMed ID: 35633141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world outcomes among patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first-line setting.
    Apple J; Shenolikar R; De Silva K; Sun P; Spira A
    Cancer Med; 2023 Jun; 12(12):13415-13425. PubMed ID: 37306623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
    Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ
    Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
    Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
    Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
    Chiang AC; Fernandes AW; Pavilack M; Wu JW; Laliberté F; Duh MS; Chehab N; Subramanian J
    BMC Cancer; 2020 Apr; 20(1):356. PubMed ID: 32345265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.